Taya et al, “Complexation Behavior of Heterocyclic Hydrazones” Bull Chem Soc Jpn, vol. 66, No. 12, 1993, pp. 3652-3661.* |
Rudolph et al, “2-hydrazino-8-quinolinol and derivatives,” J. Med. Chem., 1967, vol. 10, No. 5, p. 981.* |
F.H. Case, “Synthesis and Chelation Properties of Hydrazones Derived From Isoquinoline-1-carboxaldehyde, 2-Quinoxalinecarboxaldehyde, 4-Isoquinolylhydrazine, and 2-Quinoxalylhydrazine,” Anal. Chem. 1984, 56, pp. 2860-2862. |
I.A. Krasavin et al., “2-Formyl-8-hydroxyquinoline Derivatives,” Chemistry of Heterocyclic Compounds (English Translation), 1978, pp. 190-194. |
T. Rudolph et al., “2-Hydrazino-8-quinolinol and Derivatives,” Journal of Medicinal Chemistry, vol. 10, No. 2, Mar. 1967, p. 981. |
T. Taya et al., “Complexation Behavior of Heterocyclic Hydrazones. II. Effects of Steric Factors on Formation Constants for Nickel(11) Complexes with Heterocyclic Hydrazones,” Bul.Chem. Soc. Jpn., vol. 67, No. 3, pp. 710-719 (1994). |
Bartolucci, Cecilia et al.: “Quinolinehydrazones as Inhibitors of Retroviral Reverse Transcriptase,” II Farmaco, vol. 47(6), 1992, pp. 945-952. |
Berkoff, Charles E. et al.: “Quinolinehydrazones: Structure-Activity Correlations in a New Class of Anti-Mycoplasmal Agents,” Arzneim-Forsch. (Drug Res.) vol. 23, Nr. 6, 1973, pp. 830-839. |
Dezutter, Nancy A. et al.: “99m Tc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease,” European Journal of Nuclear Medicine, vol. 26, No. 11, Nov. 1999, pp. 1392-1399. |
Klunk, William E. et al.: “Chrysamine-G, A Lipophilic Analogue of Congo Red, Inhibits Aβ-Induced Toxicity in PC12 Cells,” Life Sciences, vol. 63, No. 20, 1998, pp. 1807-1814. |
Klunk, William E. et al.: “Chrysamine-G Binding to Alzheimer and Control brain: Autopsy Study of a New Amyloid Probe,” Neurobiology of Aging, vol. 16, No. 4, 1995, pp. 541-548. |
Klunk, William E. et al.: “Development of Small Molecule Probes for Beta-Amyloid Protein of Alzheimer's Disease” Neurobiology of Aging, vol. 15, No. 6, 1994, pp. 691-698. |
Pellerano, C. et al. “Anticestode Quinolinehydrazones,” II Farmaco-Ed.Sc., vol. 30, 1975, pp. 965-973. |
Pellerano, C. et al.: “Chinolilidrazoni di Acetilpiridine: Preparazione ed Attivita Biologica,” Boll. Chim. Farm., vol. 117, 1978, pp. 721-730. (Text is Italian with English summary at beginning of document). |
Pellerano, C. et al.: “Sintesi di Potenziali Agenti Antitumorali: Mostarde Azotate a Supporto Chinolinco,” II Farmaco-Ed.Sc., vol. 39, 1984, pp. 681-685. (Text is Italian with English summary at beginning of document). |
Pellerano, C. et al.: “Sopra Alcuni Derivati Idrazinochinolinci: 2-Chinolilidrazoni” Nota VI, Chimica Farmaceutica, Atti. Accad. Fisiocritici Siena, Serie XIV, vol. 8, 1976, pp. 81-93. (Text is Italian with English summary at end of document). |
Savini, Luisa et al.: “Chelating Agents as Potential Antitumorals: *-(N)-Heterocyclic Hydrazones and Bis-*-(N)-Heterocyclic Hydrazones,” II Farmaco, vol. 52 (10), 1997, pp. 609-613. |
Savini, Luisa et al.: “New Quinoline Derivatives: Synthesis and Evaluation for Antiinflammatory and Analgesic Properties—Note II”, II Farmaco, vol. 48, (6), 1993, pp. 805-825. |
Sawada, Geri A. et al.: “Increased Lipophilicity and Subsequent Cell Partitioning Decrease Passive Transcelluar Diffusion of Novel, Highly Lipophilic Antioxidants,” The Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 3, 1999, pp. 1317-1326. |
Skovronsky, Daniel M. et al.: “In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease,” PNAS, vol. 97, No. 13, Jun. 20, 2000, pp. 7609-7614. |